IN THE CLAIMS:

Please amend the claims pursuant to 37 C.F.R. 1.173 as follows. All changes have been indicated relative to the original claims of U.S. Patent No. 5,290,551.

F1

1. (Amended) A vaccine useful for the treatment of melanoma comprising irradiated autologous melanoma cells conjugated to a hapten, said hapten selected from the group consisting of [dinitrophenyl,] trinytrophenyl [,] and N-iodoacetyl-N'-5 sulfonic 1-naphtyl ethylene diamine; and mixed with an immunological adjuvant, wherein said immunological adjuvant is Bacille Calmette-Guerin.

2. (Amended) A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of the vaccine of claim 1, wherein said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells.

F2

21. The vaccine of claim 1, wherein said autologous melanoma cells are cryopreserved.

22. The method of claim 2, wherein said autologous melanoma cells are

F 2 cont.

cryopreserved.

23. The method of claim 2, wherein said vaccine is injected into three contiguous sites on an upper arm or leg.

24. The method of claim 2, wherein said vaccine is administered to post-surgical melanoma patients.

25. The method of claim 2, wherein said vaccine is administered to stage four melanoma patients.

26. A method for treating melanoma comprising administering cyclophosphamide followed by intradermal administration of a therapeutically effective amount of a vaccine composition comprising autologous irradiated melanoma cells conjugated to a hapten, said hapten selected from the group consisting of dinitrophenyl, trinytrophenyl, and N-iodoacetyl-N'-5 sulfonic 1-naphtyl ethylene diamine and mixed with *Bacille Calmette-Guerin*, wherein administration of said vaccine induces a delayed-type hypersensitivity (DTH) response against unmodified melanoma cells.

F-2 cont.

27. The method of claim 26, wherein said vaccine is injected into 3 contiguous sites on an upper arm or leg.

28. The method of claim 26, wherein said vaccine is administered to post-surgical melanoma patients.

29. The method of claim 26, wherein said vaccine is administered to stage four melanoma patients.

30. The method of claim 26, wherein said vaccine is administered every 4 weeks.

F3

31. (New) The method of claim 26, wherein said autologous melanoma cells are cryopreserved.